All Access Articles |
- Zymeworks strategic initiative drives stock up 29.05% | 2025-11-18 | PHARMACEUTICAL
- Zymeworks' Phase 3 Trial Shows Significant Improvements | 2025-11-17 | PHARMACEUTICAL
- Zymeworks' Zanidatamab approved for HER2+ biliary tract cancer in China | 2025-06-01 | PHARMACEUTICAL
- Zymeworks Outlines Strategic Priorities and Projects Cash Runway into 2027 | 2025-01-09 | PHARMACEUTICAL